Topics
Uncategorized
Pfister, J. .
1997. Glamorizing the psychological: The politics of the performances of modern psychological identities.
Inventing the psychological: Toward a cultural history of emotional life in America, 167-216.
Pincus, H.A.; Tanielian, T.L.; Marcus, S.C.; Ofson, M.; Zarin, D.A.; Thompson, J.; Zito, J.M. .
1998. Prescribing Trends in Psychotropic Medications: Primary Care, Psychiatry, and other Medical Specialties.
JAMA 279, 526-531.
.
1833. Moral Thermometer.
The Journal of Health and Recreation 4, 5.
Martin, B. .
1982. Feminism, Criticism, and Foucault.
New German Critique 27, 3-30.
Goleman, D.; Boyatzis, R.; McKee, A. .
2001. Primal leadership: The hidden driver of great performance.
Harvard Business Review 79, 42-51.
Association, A.P. .
2000. Diagnostic and statistical manual of mental disorders : DSM-IV-TR.
, xxxvii, 943 p..
Martin, E. .
In Press. Flexible survivors.
Anthropology Newsletter 40, 5-7.
Keeler, W. .
1983. Shame and Stage Fright in Java.
Ethos 11, 152-165.
Griffin, J. .
In Press. Looking for the prevailing wind.
Stoler, A.L. .
2004. Affective states.
A companion to the anthropology of politics, xxi, 500 p..
Dodds, E.R. .
1951. The Greeks and the irrational.
Rose, N. .
1992. Engineering the human soul: analyzing psychological expertise.
Science in Context 5, 351-369.
Benjamin, W. .
1999. The arcades project.
Merry, S.E. .
2004. Law and identity in an American colony.
Law & empire in the Pacific: Fiji and Hawaii, 123-152.
Kraus, A. .
1996. Role peformance, identity structure and psychosis in melancholic and manic-depressive patients.
Interpersonal factors in the origin and course of affective disorders, 31-47.
Tillson, T. .
1996. The CEO's disease.
Canadian Business 69, 26-31.
Rosenberg, C.E. .
1989. Body and Mind in Nineteenth-Century Medicine: Some Clinical Origins of the Neurosis Construct.
Bulletin of the History of Medicine 63, 185-197.
Brink, S. .
2003. CEO Sufferings Trickle Down.
U.S. News and World Report 135, 60.
Morrow, D. .
In Press. SmithKline and American Home are talking of huge drug merger.
The New York Times D, 1,5.
